Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern
Koen, A. L.; Izu, A.; Baillie, V.; Kwatra, G.; Cutland, C. L.; Fairlie, L.; Padayachee, S. D.; Dheda, K.; Barnabas, S. L.; Bhorat, Q. E.; Briner, C.; Ahmed, K.; Bhikha, S.; Bhiman, J. N.; du Plessis, J.; Esmail, A.; Horne, E.; Hwa, S.-H.; Oomen-Jose, A.; Lambe, T.; Laubscher, M.; Malahleha, M.; Benade, G.; McKenzie, S.; Oelofse, S.; Patel, F.; Pillay, S.; Rhead, S.; Rodel, H.; Taoushanis, C.; Tegally, H.; Thombrayil, A.; Villafana, T.; Gilbert, S.; Pollard, A. J.; Madhi, S.
Show abstract
In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-type and 77.1% against the Delta variant [≥]9 months after vaccination. VE against infection with the Beta variant, which preceded circulation of Delta, was 6.7%. Clinical trial identifierCT.gov NCT04444674
Matching journals
The top 4 journals account for 50% of the predicted probability mass.